After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.

Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday. A widely ...

U.S.-listed shares of BioNTech SE ended Monday nearly 3.2% lower, weighed down by a weak full-year revenue projection even as the German drugmaker posted a quarterly earnings beat. Retail traders, ...

Phase 3 clinical trial cohort of adults 65+ and 18-64 with at least one underlying risk condition shows at least a 4-fold increase in LP.8.1-neutralizing antibody titers after receiving the ...

LP.8.1 variant adapted COVID-19 vaccine COMIRNATY is now authorized in Canada for individuals 6 months of age and older. It is expected to be available in Canada in the coming weeks. This season's ...

BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech at $1.25 billion. The announcement makes no specific mention of onboarding ...

Last week, the European Union (EU) through Team Europe announced an €95 million (approximatelyRwf160bn) funding commitment to Rwanda to enable the country to scale its vaccine manufacturing efforts.

Nov 13 (Reuters) - Pfizer Inc (PFE.N), opens new tab said on Thursday it sold a part of its stake in German drugmaker BioNTech SE (22UAy.DE), opens new tab, more than five years after both firms ...